Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Stephen C Bain

Showing results (91-100 of 129) with videos related to

Pageof 13
Sort By:
The Journal of Sports Medicine and Physical Fitness|July 30, 2015
Improved end-stage high-intensity performance but similar glycemic responses after waxy barley starch ingestion compared to dextrose in type 1 diabetesBenjamin J Gray, Rhydian Page, Daniel Turner, et al.
Diabetes, Obesity & Metabolism|May 7, 2020
The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trialsLawrence A Leiter, Stephen C Bain, Deepak L Bhatt, et al.
Diabetes, Obesity & Metabolism|March 10, 2019
Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trialsSubodh Verma, Stephen C Bain, Tea Monk Fries, et al.
Diabetes Care|July 21, 2018
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled TrialChantal Mathieu, Paresh Dandona, Pieter Gillard, et al.
Diabetes, Obesity & Metabolism|July 10, 2020
Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trialsSubodh Verma, Stephen C Bain, Julie Broe Honoré, et al.
Diabetes, Obesity & Metabolism|October 8, 2025
Addressing the risk of ocular complications of GLP-1RAs; a multi-disciplinary expert consensusPatrice Carter, Rafael Simó, Monica Lövestam-Adrian, et al.
Advances in Therapy|November 5, 2021
A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future PerspectivesMarc Evans, Ruth D Lewis, Angharad R Morgan, et al.
Plos One|May 27, 2014
Metabolic implications when employing heavy pre- and post-exercise rapid-acting insulin reductions to prevent hypoglycaemia in type 1 diabetes patients: a randomised clinical trialMatthew D Campbell, Mark Walker, Michael I Trenell, et al.
Drugs|December 21, 2021
New Therapeutic Horizons in Chronic Kidney Disease: The Role of SGLT2 Inhibitors in Clinical PracticeMarc Evans, Angharad R Morgan, Martin B Whyte, et al.
Journal of the American College of Cardiology|March 14, 2020
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart FailureSteven P Marso, Florian M M Baeres, Stephen C Bain, et al.
Pageof 13

Showing results (91-100 of 129) with videos related to

Sort By:
Pageof 13
The Journal of Sports Medicine and Physical Fitness|July 30, 2015
Improved end-stage high-intensity performance but similar glycemic responses after waxy barley starch ingestion compared to dextrose in type 1 diabetesBenjamin J Gray, Rhydian Page, Daniel Turner, et al.
Diabetes, Obesity & Metabolism|May 7, 2020
The effect of glucagon-like peptide-1 receptor agonists liraglutide and semaglutide on cardiovascular and renal outcomes across baseline blood pressure categories: Analysis of the LEADER and SUSTAIN 6 trialsLawrence A Leiter, Stephen C Bain, Deepak L Bhatt, et al.
Diabetes, Obesity & Metabolism|March 10, 2019
Duration of diabetes and cardiorenal efficacy of liraglutide and semaglutide: A post hoc analysis of the LEADER and SUSTAIN 6 clinical trialsSubodh Verma, Stephen C Bain, Tea Monk Fries, et al.
Diabetes Care|July 21, 2018
Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled TrialChantal Mathieu, Paresh Dandona, Pieter Gillard, et al.
Diabetes, Obesity & Metabolism|July 10, 2020
Impact of microvascular disease on cardiovascular outcomes in type 2 diabetes: Results from the LEADER and SUSTAIN 6 clinical trialsSubodh Verma, Stephen C Bain, Julie Broe Honoré, et al.
Diabetes, Obesity & Metabolism|October 8, 2025
Addressing the risk of ocular complications of GLP-1RAs; a multi-disciplinary expert consensusPatrice Carter, Rafael Simó, Monica Lövestam-Adrian, et al.
Advances in Therapy|November 5, 2021
A Narrative Review of Chronic Kidney Disease in Clinical Practice: Current Challenges and Future PerspectivesMarc Evans, Ruth D Lewis, Angharad R Morgan, et al.
Plos One|May 27, 2014
Metabolic implications when employing heavy pre- and post-exercise rapid-acting insulin reductions to prevent hypoglycaemia in type 1 diabetes patients: a randomised clinical trialMatthew D Campbell, Mark Walker, Michael I Trenell, et al.
Drugs|December 21, 2021
New Therapeutic Horizons in Chronic Kidney Disease: The Role of SGLT2 Inhibitors in Clinical PracticeMarc Evans, Angharad R Morgan, Martin B Whyte, et al.
Journal of the American College of Cardiology|March 14, 2020
Effects of Liraglutide on Cardiovascular Outcomes in Patients With Diabetes With or Without Heart FailureSteven P Marso, Florian M M Baeres, Stephen C Bain, et al.
Pageof 13